ストックスクリーナーアプリを入手
2.02
0.98%
-0.02
アフターアワーズ：
2.04
0.02
+0.99%
前日終値:
$2.04
開ける：
$2.04
24時間の取引高:
2.10M
Relative Volume:
0.52
時価総額：
$602.95M
収益：
$38.03M
当期純損益:
$-146.40M
株価収益率:
-3.8846
EPS:
-0.52
ネットキャッシュフロー:
$-121.38M
1週間 パフォーマンス:
+2.54%
1か月 パフォーマンス:
-20.78%
6か月 パフォーマンス:
-32.89%
1年 パフォーマンス:
-50.00%
1日の値動き範囲:
$1.98
$2.04
1週間の範囲:
$1.965
$2.08
52週間の値動き範囲:
$1.8906
$4.20
Abcellera Biologics Inc Stock (ABCL) Company Profile
ABCL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.02 | 588.01M | 38.03M | -146.40M | -121.38M | -0.52 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - Insider Monkey
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - BioSpace
AbCellera Biologics Receives Health Canada Approval for Trial - TipRanks
AbCellera Biologics Gets Health Canada Authorization for Phase 1 Trial of Dermatitis Treatment - marketscreener.com
AbCellera Receives Authorization from Health Canada to Initiate - GuruFocus
AbCellera (ABCL) Gains Health Canada Approval for Clinical Trial - GuruFocus
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 | ABCL Stock News - GuruFocus
AbCellera gains Health Canada nod for AD antibody trial - Investing.com
Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment - Stock Titan
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - MSN
AbCellera Biologics Inc. raises US$100M in series A2 financing - McCarthy Tétrault
Truist cuts AbCellera stock target to $10, maintains Buy By Investing.com - Investing.com South Africa
Truist Securities Lowers Price Target for AbCellera Biologics (A - GuruFocus
Truist cuts AbCellera stock target to $10, maintains Buy - Investing.com Australia
Truist Securities Lowers Price Target for AbCellera Biologics (ABCL) | ABCL Stock News - GuruFocus
Truist Adjusts Price Target for AbCellera (ABCL) Amid Strategic Shift | ABCL Stock News - GuruFocus
Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates - simplywall.st
Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) - Yahoo Finance
AbCellera to begin Phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment - marketscreener.com
AbCellera to begin Phase 1 trial for menopause treatment - Investing.com
AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Trea - GuruFocus
AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Treatment | ABCL Stock News - GuruFocus
AbCellera Receives Authorization From Health Canada To Initiate The Phase 1 Clinical Trial Of Abcl635 For Vasomotor Symptoms Due To Menopause - marketscreener.com
AbCellera patent upheld in Federal Circuit Court ruling By Investing.com - Investing.com Nigeria
AbCellera Wins Patent Appeal Against Bruker - TipRanks
AbCellera's Platforms - AbCellera
Making medicines together. We collaborate with partners to create differentiated antibody medicines. - AbCellera
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by t - GuruFocus
AbCellera (ABCL) Wins Patent Validation Case in Federal Circuit - GuruFocus
AbCellera patent upheld in Federal Circuit Court ruling - Investing.com Australia
Abcellera's Microfluidic Cell Culture Patent Affirmed Valid By U.S. Court Of Appeals For Federal Circuit - marketscreener.com
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - BioSpace
AbCellera plans to advance ABCL635 and ABCL575 into Phase 1 trials in Q3 2025 - MSN
AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Call Transcript - Insider Monkey
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2 - GuruFocus
Stifel Adjusts Price Target for AbCellera (ABCL), Maintains Buy Rating | ABCL Stock News - GuruFocus
AbCellera Biologics Navigates Progress and Challenges in Earnings Call - TipRanks
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates - MSN
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting | ABCL Stock News - GuruFocus
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):